amifostine + irinotecan

Amifostine + irinotecan is an investigational combination therapy consisting of amifostine, a cytoprotective agent, and irinotecan, a topoisomerase I inhibitor chemotherapeutic. Amifostine acts as a prodrug that is dephosphorylated in tissues to its active metabolite WR-1065, which scavenges free radicals and protects normal tissues from the toxic effects of chemotherapy and radiation. Irinotecan inhibits DNA topoisomerase I, leading to DNA damage and apoptosis in rapidly dividing cancer cells. The combination has been studied primarily for its potential to reduce the gastrointestinal toxicity (notably diarrhea) associated with irinotecan treatment in cancer patients[1][3]. Clinical trials have evaluated this regimen in metastatic colorectal carcinoma and pediatric refractory solid tumors; however, results indicate that while amifostine may offer some myeloprotection or mucosal protection allowing for dose escalation of irinotecan when used with other agents like cisplatin, it does not significantly reduce all toxicities associated with irinotecan[1][2][3].